CHILDHOOD CANCER RESEARCH NEWSRecently Publicised - Media Coverages About Childhood Cancer Research Program Tweet
Showing 1 to 5 of 22 on page #1
Michael Cuccione Foundation Fellowship Recipients Announced
June 27, 2014
Gloria Cuccione to receive 2014 Order of British Columbia
Source: Order of British Columbia, May 28, 2014
"Gloria Cuccione has been instrumental in the creation and ongoing success of the Michael Cuccione Foundation, named after her late son. Since the foundation's creation in 1997, it has raised – together with grants and matching funds – more than $15 million toward pediatric oncology research."
"The Order of British Columbia is the province's most prestigious accolade," said Guichon. "For 25 years, we have publicly recognized those who have dedicated themselves to bettering the lives of their fellow citizens. These recipients exemplify the positive difference one person can make in a community and are an inspiration to all British Columbians."
"The Order of British Columbia recognizes remarkable accomplishments by extraordinary British Columbians," said Premier Christy Clark. "On behalf of all British Columbians, I want to thank this year's recipients for their dedication – and all they do to make B.C. better."
Childhoood Cancer Research Impact Report
May 27, 2014
2014 REPORT ON GIVING FOR THE Michael Cuccione Foundation is released. The Michael Cuccione Childhood Cancer Research Program is located within the Child & Family Research Institute (CFRI) at BC Children's Hospital in Vancouver. The collaborative relationships between clinicians and researchers in the hospital and CFRI are essential to the pursuit of breakthrough cancer discoveries.
Advances made in the treatment of many childhood cancers since the 1980s have greatly improved survival rates – as high as 82 per cent for children with certain types of cancers. These advances have largely been made possible through investments, like yours, in research.
Leukemias, lymphomas and central nervous system cancers (including brain cancers) are the main types of cancer affecting children in Canada. In BC, 142 children were diagnosed with cancer last year, an increase from recent years, which makes your support more critical now than ever. All of these children receive care at BC Children's Hospital and benefit from having access to clinical trials for the newest cancer therapies being developed by MCCCRP and CFRI researchers.
Thankfully, more children today survive cancer than ever before. Still, many of them will endure life-threatening adverse side effects, caused either by the cancer itself or the cancer-fighting drugs they receive. These ong-term complications can affect growth and development, learning, the heart and organs, bones and fertility, and the child's chances of subsequent cancers.
The researchers you are supporting aim to develop improved therapies that are safer, less invasive and do not damage a child's developing body. The ultimate goal of the MCCCRP team is to achieve Michael's dream and discover a cure for childhood cancer.
Improving Survival in Childhood Leukemia
Source: Canadian Institutes of Health Research, April 18, 2014
Dr. Kirk Schultz is finding ways to reduce and predict rejection after bone marrow transplant.
The Evidence Maker: Dr. Kirk Schultz is a pediatric oncologist who studies childhood leukemia. He has a keen interest in finding ways to improve leukemia treatments and reduce the long-term side effects of treatments.
The Question: When chemotherapy fails, blood and marrow transplant (BMT) is the next most effective treatment for childhood leukemia, but unfortunately, it can come at a cost – graft-versus-host disease (GVHD). With GVHD, the immune system attacks the transplanted bone marrow and patients need lifelong treatments to stop the immune system from attacking the implanted bone marrow cells. Dr. Schultz is exploring what treatment strategies can be developed to improve outcomes and reduce side effects – and lead to more targeted and personalized treatments.
Source: Science Magazine, December 22, 2013
This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark. History's path is unchartable when it's not yet past but present, when we are still standing in the middle of it. That's what made Science's selection of this year’s Breakthrough of the Year such a topic of internal debate, even anxiety. In celebrating cancer immunotherapy-harnessing the immune system to battle tumors-did we risk hyping an approach whose ultimate impact remains unknown? Were we irresponsible to label as a breakthrough a strategy that has touched a tiny fraction of cancer patients and helped only some of them? What do we mean when we call something a breakthrough, anyway?
|1 2 3 4 5|